West Pharmaceutical Services Inc. Common Stock (WST): valor razonable

Tesis ACCE

West Pharmaceutical Services makes the elastomer components that sit between a drug and the patient: stoppers and seals for vials and prefilled syringes, plus the Daikyo and self-injection device lines, many of them specified into biologics and GLP-1 injectables. Its moat is qualification rather than capacity: once a drug maker validates a West component in a filled container, switching means re-running stability and regulatory work, so contracts tend to persist for the life of the molecule. The near-term driver is the injectable boom, with demand for high-value prefilled syringes and autoinjectors growing faster than the broader pharma base. Revenue growth of 13.8% and a 22.5% operating margin show that this is still translating into profit, with ROE at 19.1%. The stock trades at 47.1 times trailing earnings and 36.8 times forward, so the premium already prices in sustained growth. It is not in any major index, which may limit passive demand, and the multiple leaves little room for a slowdown in injectable volumes or a reset in customer ordering.